

35 - References

References

Prescribing in children and adolescents CHAPTER 5 References

1. National Institute for Health and Clinical Excellence. Attention deficit hyperactivity disorder: diagnosis and management. NICE Guideline [NG87]. 2018 (last updated September 2019, last accessed December 2023); <https://www.nice.org.uk/guidance/NG87>.
2. Carucci S, et al. Long term methylphenidate exposure and growth in children and adolescents with ADHD. A systematic review and meta- analysis. *Neurosci Biobehav Rev* 2021; 120:509–525.
3. Biederman J, et al. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. *Biol Psychiatry* 2007; 62:970–976.
4. Coghill D, et al. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/ hyperactivity disorder. *Eur Neuropsychopharmacol* 2013; 23:1208–1218.
5. Findling RL, et al. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry* 2011; 50:395–405.
6. Heal DJ, et al. Amphetamine, past and present – a pharmacological and clinical perspective. *J Psychopharmacol* 2013; 27:479–496.
7. Coghill DR, et al. Long-term safety and efficacy of lisdexamfetamine dimesylate in children and adolescents with ADHD: a phase IV, 2-year, open-label study in Europe. *CNS Drugs* 2017; 31:625–638.
8. Joseph A, et al. Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison. *Eur Child Adolesc Psychiatry* 2017; 26:875–897.
9. Cortese S, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. *Lancet Psychiatry* 2018; 5:727–738.
10. Findling RL, et al. Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/ hyperactivity disorder. *CNS Spectr* 2008; 13:614–620.
11. Childress AC, et al. Efficacy and safety of lisdexamfetamine in preschool children with attention-deficit/hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry* 2022; 61:1423–1434.

12. Michelson D, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. *Am J Psychiatry* 2002; 159:1896–1901.
13. Kratochvil CJ, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. *J Am Acad Child Adolesc Psychiatry* 2002; 41:-776–784.
14. Weiss M, et al. A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. *J Am Acad Child Adolesc Psychiatry* 2005; 44:647--655.
15. Kratochvil CJ, et al. A double-blind, placebo-controlled study of atomoxetine in young children with ADHD. *Pediatrics* 2011; 127:e862–e868.
16. Catala-Lopez F, et al. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: a systematic review with network meta-analyses of randomised trials. *PLoS One* 2017; 12:e0180355.
17. Liu Q, et al. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials. *J Clin Exp Neuropsychol* 2017; 39:854–865.
18. Yu S, et al. Guanfacine for the treatment of attention-deficit hyperactivity disorder: an updated systematic review and meta-analysis. *J Child Adolesc Psychopharmacol* 2023; 33:40–50.
19. Radonjic ´ NV, et al. Nonstimulant medications for attention-deficit/hyperactivity disorder (ADHD) in adults: systematic review and meta- analysis. *CNS Drugs* 2023; 37:381–397.
20. Connor DF, et al. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry* 1999; 38:1551–1559.
21. Hazell P. Tricyclic antidepressants in children: is there a rationale for use? *CNS Drugs* 1996; 5:233–239.
22. Otasowie J, et al. Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents. *Cochrane Database Syst Rev* 2014; 9:CD006997.
23. Gorman DA, et al. Canadian guidelines on pharmacotherapy for disruptive and aggressive behaviour in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, or conduct disorder. *Can J Psychiatry* 2015; 60:62–76.
24. Ng QX. A systematic review of the use of bupropion for attention-deficit/hyperactivity disorder in children and adolescents. *J Child Adolesc Psychopharmacol* 2017; 27:112–116.
25. Biederman J, et al. A comparison of once-daily and divided doses of modafinil in children with attention-deficit/hyperactivity disorder: a randomized, double-blind, and placebo--controlled study. *J Clin Psychiatry* 2006; 67:727–735.
26. Wang SM, et al. Modafinil for the treatment of attention-deficit/hyperactivity disorder: a meta-analysis. *J Psychiatr Res* 2017; 84:292–300.
27. Nasser A, et al. A phase III, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of viloxazine extended-release capsules in adults with attention--deficit/hyperactivity disorder. *CNS Drugs* 2022; 36:897–915.
28. Einarson TR, et al. Novel Antipsychotics for Patients with Attention-Deficit Hyperactivity Disorder: a Systematic Review. Technology Report No. 17. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 2001.
29. Pringsheim T, et al. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity

disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 2: antipsychotics and traditional mood stabilizers. *Can J Psychiatry* 2015; 60:52-61.

30. Ji N, et al. An update on pharmacotherapy for autism spectrum disorder in children and adolescents. *Curr Opin Psychiatry* 2015; 28:91-101.
31. Pozzi M, et al. Emerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD). *Expert Opin Emerg Drugs* 2020; 25:395-407.
32. Humphreys KL, et al. Stimulant medication and substance use outcomes: a meta-analysis. *JAMA Psychiatry* 2013; 70:740-749.

604 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 5

33. Treuer T, et al. A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability. *J Child Adolesc Psychopharmacol* 2013; 23:179-193.
34. McCracken JT, et al. Combined stimulant and guanfacine administration in attention-deficit/hyperactivity disorder: a controlled, comparative study. *J Am Acad Child Adolesc Psychiatry* 2016; 55:657-666.e651.
35. Zhang L, et al. Risk of cardiovascular diseases associated with medications used in attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. *JAMA Network Open* 2022; 5:e2243597.
36. Zhang L, et al. Attention-deficit/hyperactivity disorder medications and long-term risk of cardiovascular diseases. *JAMA Psychiatry* 2024; 81:178-187.
37. Wolraich ML, et al. Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate. *CNS Drugs* 2004; 18:243-250.
38. Joint Formulary Committee. British National Formulary (online). London: BMJ and Pharmaceutical Press; <http://www.medicinescomplete.com>.
39. Janssen-Cilag Ltd. Summary of product characteristics. Concerta XL 18mg, 27mg, 36mg and 54mg prolonged-release tablets. 2023; <https://www.medicines.org.uk/emc/product/6872/smpc>.
40. Efron D, et al. Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. *Pediatrics* 1997; 100:662-666.
41. Hennissen L, et al. Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with ADHD: a systematic review and meta-analysis of trials of methylphenidate, amphetamines and atomoxetine. *CNS Drugs* 2017; 31:199-215.
42. Gadow KD, et al. Efficacy of methylphenidate for attention-deficit hyperactivity disorder in children with tic disorder. *Arch Gen Psychiatry* 1995; 52:444-455.
43. Cohen SC, et al. Meta-analysis: risk of tics associated with psychostimulant use in randomized, placebo-controlled trials. *J Am Acad Child Adolesc Psychiatry* 2015; 54:728-736.
44. Hoare P, et al. 12-month efficacy and safety of OROS MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH. *Eur Child Adolesc Psychiatry* 2005; 14:305-309.
45. Remschmidt H, et al. Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS MPH. Results of a 3-week open-label study. *Eur Child Adolesc Psychiatry* 2005; 14:297-304.
46. Wolraich ML, et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder. *Pediatrics* 2001; 108:883-892.
47. Findling RL, et al. Comparison of the clinical efficacy of twice-daily Ritalin and once-daily Equasym XL with placebo in children with attention deficit/hyperactivity disorder. *Eur Child Adolesc Psychiatry* 2006; 15:450-459.
48. Anderson VR, et al. Spotlight on methylphenidate controlled-delivery capsules (Equasym XLTM) in the treatment of children and adolescents with attention-deficit hyperactivity disorder. *CNS Drugs* 2007; 21:173-175.
49. Flynn Pharma Ltd. Summary of product characteristics. Medikinet XL 5mg, 10mg, 20mg, 30mg, 40mg, 50mg and 60mg modified release capsules (methylphenidate hydrochloride). 2023; <https://www.medicines.org.uk/emc/product/313/smpc>.
- 50.

Medicines and Healthcare products Regulatory Agency. Public assessment report. Ritalin XL 10mg, 20mg, 30mg, 40mg, 60mg modified- release hard capsules (last updated March 2014); <https://mhraproductsproduction.blob.core.windows.net/docs/4781baf366b1fafd0ea203962ccb54faadcdfcc>. 51. Cyr M, et al. Current drug therapy recommendations for the treatment of attention deficit hyperactivity disorder. *Drugs* 1998; 56:215–223. 52. Takeda UK Ltd. Summary of product characteristics. Elvanse 20mg, 30mg, 40mg, 50mg, 60mg and 70mg capsules, hard (lisdexafetamine). 2023; <https://www.medicines.org.uk/emc/product/14091/smpc>. 53. Kelsey DK, et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. *Pediatrics* 2004; 114:e1–e8. 54. Wernicke JF, et al. Cardiovascular effects of atomoxetine in children, adolescents, and adults. *Drug Saf* 2003; 26:729–740. 55. Heil SH, et al. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. *Drug Alcohol Depend* 2002; 67:149–156. 56. Reed VA, et al. The safety of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a comprehensive review of over a decade of research. *CNS Drugs* 2016; 30:603–628. 57. Childress A, et al. Evaluation of the current data on guanfacine extended release for the treatment of ADHD in children and adolescents. *Expert Opin Pharmacother* 2020; 21:417–426. 58. Takeda UK Ltd. Guanfacine modified-release. Personal communication, 2020. 59. Cortese S, et al. New formulations of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: pharmacokinetics, efficacy, and tolerability. *CNS Drugs* 2017; 31:149–160.

Revision #1

Created 2026-01-04 20:16:41 UTC by Omar Ayman

Updated 2026-01-04 20:16:41 UTC by Omar Ayman